Angioplasty Balloon Market Size & Growth Forecast (2027–2034) by Product, Material, Application, End Use and Region
REPORT DETAILS
Angioplasty Balloons Market Summary
The global angioplasty balloon market is estimated at USD 2.98 billion in 2026 and is projected to reach USD 3.08 billion in 2027, expanding to USD 3.91 billion by 2034 at a CAGR of 3.5% during 2027–2034. The rising burden of coronary and peripheral artery disease is increasing the number of percutaneous interventions performed each year. Drug-coated balloons are gaining ground as a 'leave nothing behind' option for in-stent restenosis and small-vessel disease, lifting average selling prices.
Market Statistics
Key Takeaways
• Normal (plain) balloons hold the largest product share, an estimated 51.2% of revenue in 2026, because they are used in nearly every angioplasty and pre-dilation procedure.
• Drug-coated balloons are the fastest-growing product type, at an estimated 39.2% share in 2026, as they gain approvals for in-stent restenosis and small-vessel disease.
• Coronary Angioplasty leads applications with an estimated 66.4% share, while peripheral artery disease is expanding with more below-the-knee interventions.
• Hospitals are the dominant end users, at an estimated 82.6% share, although ambulatory surgery centres and office-based labs are gaining peripheral procedures.
• North America holds the largest regional share, at an estimated 37.5% in 2026, supported by high PCI volumes and early DCB approvals.
• Asia Pacific is expected to grow fastest, currently at an estimated 23.5%, driven by rising cardiovascular disease and expanding cath-lab capacity in China and India.
• The competitive field is led by large cardiovascular device companies, with scoring balloons and DCBs the main battleground for differentiation.
The factors such as the rising number of cardiac diseases and the adoption of angioplasty balloons to treat coronary and peripheral artery illnesses are expected to boost the angioplasty balloons industry growth during the forecast period.

Know more about this report: Download Sample Report
Angioplasty balloons became the treatment of choice for individuals suffering from coronary and peripheral artery illnesses as the number of cases of artery disease rises. Coronary artery disease is a life-threatening condition caused by a lack of blood supply to the heart, resulting in cardiac arrest.
Angioplasty is a procedure that involves inserting a tiny balloon-tipped catheter into a blood vessel and inflating it at the blockage location to ensure open the restricted arteries. Furthermore, angioplasty balloons have a greater success rate than traditional angioplasty techniques, which is expected to drive market expansion.
Further, cardiac disorders are on the rise at an alarming rate, necessitating precise treatment options with high success rates. For instance, according to the World Health Organization (WHO), CVDs impacted the lives of around 17.9 million people across the globe, representing 32% of all deaths. Heart-related ailments and strokes accounted for most of the 85% of deaths.
Furthermore, a rising elderly population with heart disease and diabetes is predicted to drive up the demand for angioplasty catheters. However, the market is projected to be hampered by high costs and post-operative problems associated with angioplasty.
Industry Dynamic
Minimal invasive surgery has numerous advantages: less pain, swift recovery, smaller incisions, reduced hospital stay, and consequent medical costs. The rising geriatric population with the increasing prevalence of CVD will lead to the demand for minimally invasive treatment, which further propels the market's growth. As per the statistics published by Ageing Asia, the Vietnamese population aged 60 and above is projected to rise by 29,841,000 in 2050.
Similarly, the market is growing due to the increased frequency of lifestyle-related illnesses and the growing geriatric population. As per AgeingAsia.org, the geriatric population aged 60 and above in Myanmar was 5,443,000 in 2019 and is expected to rise to 62,253,000 in 2050. Thus, the growing geriatric population in emerging countries presents an increased demand for CVD treatment, augmenting the growth of the interventional cardiology market. Moreover, domestic and localized market players' new developments, product pipeline analysis, and initiatives for innovative treatment options have tremendously boosted the market growth.

Know more about this report: Download Sample Report
Report Segmentation
The market is primarily segmented based on product type, application, end-user, and region.
| By Product Type | By Application | By End-User | By Region |
|
|
|
|
Source: Polaris Market Research Analysis
Know more about this report: Download Sample Report
Insight by Product Type
The normal segment is expected to be the most significant revenue contributor. The segment is booming because of the inexpensive cost of these devices, supporting government regulations and approval processes, and favorable reimbursement policies.
Additionally, Low-cost Drug-eluting balloons (DEBs) and various advantages of DEBs over other types, as well as new product introductions, have all helped the segment's rise. In addition, due to key companies' significant investment in research & development, the cutting and scoring type sector is predicted to increase significantly throughout the projection period.
Geographic Overview
In terms of geography, North America had the largest revenue share. The primary drivers of the market across the globe include the presence of significant market players, rising healthcare expenditure, and a growing amount of percutaneous coronary interventions. According to the American Heart Association (AHA), heart-related ailments killed 1 out of every 7 people in the U.S. in 2018.
CHDs were the largest cause of mortality among cardiovascular diseases, accounting for 43.8% of deaths, followed by heart failure (9.0%), high blood pressure (9.4%), artery diseases (3.1%), and other cardiovascular diseases (17.9%). As a result, there is a growing desire for better treatment with innovative medical equipment, which is a primary driver of the market under consideration.
Furthermore, the region is a hotbed of technological breakthroughs and new product inventions for catheters and angioplasty balloons, which aids in the growth of the angioplasty balloons market. As a result, the market in the region is the largest in the world.
Moreover, Asia Pacific is expected to witness a high CAGR in the global angioplasty balloons market. This is due to the presence of the world's enormous population in this region, which includes a significant number of people suffering from heart disease. In India, Japan, and China, the cost of an angioplasty balloon has reduced by roughly 40% in the last decade, indicating that the angioplasty balloons market in Asia-Pacific is growing.
List Of Key Players
- Abbott Laboratories
- AngioDynamics
- B. Braun Melsungen AG.
- Becton Dickinson
- Biomerics
- BIOTRONIK Vertriebs GmbH & Co. KG
- Boston Scientific Corporation
- Cardinal Health
- Cordis (Cardinal Health)
- CTK biotech, Inc
- Hexacath
- INFINITY Angioplasty Balloon
- JOTEC GmbH
- Koninklijke Philips N.V
- Medtronic Plc
- MicroPort Scientific Corporation
- Nipro Medical Corporation
Recent Developments
In October 2025, Orchestra BioMed began enrolling patients in the U.S. pivotal Virtue Trial for its Virtue Sirolimus AngioInfusion Balloon, a new angioplasty balloon that delivers a sustained-release liquid formulation of sirolimus directly into the coronary vessel wall. Unlike conventional drug-coated balloons, Virtue SAB does not rely on a drug coating on the balloon surface; instead, its microporous balloon delivers sirolimus during angioplasty without leaving behind a permanent implant. The pivotal trial is expected to enroll approximately 740 patients across as many as 75 U.S. centers and directly compare Virtue SAB with Boston Scientific’s AGENT paclitaxel-coated balloon for coronary in-stent restenosis. (Source: Orchestra BioMed)
In July 2025, Teleflex completed the acquisition of substantially all of BIOTRONIK’s Vascular Intervention business, adding drug-coated balloon platforms including Pantera Lux for coronary intervention and Passeo-18 Lux for peripheral intervention to its portfolio. The transaction significantly expanded Teleflex’s presence in both coronary and peripheral vascular procedures and gave the company a broader range of interventional products across drug-coated balloons, stents and other catheter-based technologies. Teleflex has subsequently identified drug-coated balloons as an important growth area and stated its intention to expand the availability of its coronary and peripheral DCB technologies into additional markets, including the United States. (Source: Teleflex Incorporated)
Angioplasty Balloons Market Report Scope
| Report Attributes | Details |
| Market size value in 2027 | USD 3.08 Billion |
| Revenue forecast in 2030 | USD 3.91 Billion |
| CAGR | 3.5% from 2027 - 2034 |
| Base year | 2026 |
| Historical data | 2021-2025 |
| Forecast period | 2027 - 2034 |
| Quantitative units | Revenue in USD million and CAGR from 2027 to 2034 |
| Segments covered | By Product Type, By Application, By End-Use, By Region |
| Regional scope | North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
| Key Companies | Abbott Laboratories, AngioDynamics, B. Braun Melsungen AG., Becton Dickinson, Biomerics, BIOTRONIK Vertriebs GmbH & Co. KG, Boston Scientific Corporation, Cardinal Health, Cordis (Cardinal Health), CTK biotech, Inc, Hexacath, INFINITY Angioplasty Balloon, JOTEC GmbH, Koninklijke Philips N.V, Medtronic Plc, MicroPort Scientific Corporation, and Nipro Medical Corporation. |
Source: Polaris Market Research Analysis
Angioplasty Balloon Market FAQ's
The industry will grow at a CAGR of 3.4% from 2022-2030.
Market valued at USD 2.55 billion in 2021 and expected to reach USD 3.44 billion by 2030.
Rising cardiac diseases, increasing geriatric population, minimal invasive surgery benefits, and growing adoption of angioplasty balloons for coronary and peripheral artery treatments.
Drug-eluting balloons adoption, technological advancement in balloon catheters, growing preference for minimally invasive procedures, and cost reduction in emerging markets.
Research & development in innovative balloon technologies, emerging markets expansion in Asia Pacific, development of low-cost drug-eluting balloons, and favorable reimbursement policies.
The angioplasty balloon market is valued at USD 2.98 billion in 2026 and is expected to reach USD 3.08 billion in 2027 and USD 3.91 billion by 2034, according to Polaris Market Research.
The angioplasty balloon market is projected to grow at a CAGR of 3.5% from 2027 to 2034, adding roughly USD 0.83 billion in value over the forecast period.
The rising burden of coronary and peripheral artery disease is increasing the number of percutaneous interventions performed each year. Drug-coated balloons are gaining ground as a 'leave nothing behind' option for in-stent restenosis and small-vessel disease, lifting average selling prices.
The main applications are coronary artery disease, peripheral artery disease, in-stent restenosis, and AV-fistula/dialysis access. Drug-coated balloons are moving value up the product mix.
Download Sample Report of Angioplasty Balloons Market
Please fill out the form to request a customized copy of the research report.